|
Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes. |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
Valeriy Vladimirovich Breder |
Honoraria - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda |
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
Fedor Vladimirovich Moiseenko |
Honoraria - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer/EMD Serono; Roche; Sanofi/Aventis; Takeda |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche; Takeda |
Research Funding - BioCad (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Sanofi/Aventis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Travel, Accommodations, Expenses - AstraZeneca; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Takeda (Inst) |